JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Overexpression of MicroRNA-31 as a Promising Biomarker for Prognosis and Metastasis in Human Colorectal Cancer
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
  • Journal title : Journal of Life Science
  • Volume 26, Issue 6,  2016, pp.705-710
  • Publisher : Korean Society of Life Science
  • DOI : 10.5352/JLS.2016.26.6.705
 Title & Authors
Overexpression of MicroRNA-31 as a Promising Biomarker for Prognosis and Metastasis in Human Colorectal Cancer
Hur, Keun;
  PDF(new window)
 Abstract
Colorectal cancer (CRC) is the third most common cancer and a leading cause of cancer-related death worldwide. Although several diagnostic and therapeutic tools have been available, CRC remains difficult to complete cure because of insufficient understanding of the molecular mechanisms underlying this disease progression. MicroRNAs (miRNAs) are small non-coding RNA molecules that strongly regulate gene expression via transcriptional and translational control mechanisms. Many crucial cellular pathways are frequently disrupted in cancer development process due to dysregulation of several miRNAs. Mir-31 functions as an oncogene that modulate expression of multiple cancer related genes. Thus, we aimed to demonstrate clinical relevance of miR-31 in human CRC. Quantitative RT-PCR analysis of miR-31 expression was performed in 175 CRC tissues and 16 normal colonic mucosa (NM). Next, we investigated clinical significances of miR-31 expression in various clinicopathologic features in CRC patients cohort. Mir-31 was significantly up-regulated in CRC tissues compared to NM. In CRC tissues, miR-31 expression level was significantly elevated in a stage-dependent manner, which was associated with poor survival in patients with CRC. High miR-31 levels in CRC tissues significantly correlated with poor prognosis (hazard ratio [HR]=2.4) as well as distant metastasis (odds ratio [OR]=2.3). In conclusion, we identified clinical significance of miR-31 expression in CRC. High miR-31 expression may be clinically able to use as a biomarker for CRC prognosis and predicting metastasis.
 Keywords
Biomarker;colorectal cancer;metastasis;MicroRNA-31;prognosis;
 Language
Korean
 Cited by
 References
1.
Asangani, I. A., Rasheed, S. A., Nikolova, D. A., Leupold, J. H., Colburn, N. H., Post, S. and Allgayer, H. 2008. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 27, 2128-2136. crossref(new window)

2.
Augoff, K., McCue, B., Plow, E. F. and Sossey-Alaoui, K. 2012. miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer. Mol. Cancer 11, 5. crossref(new window)

3.
Bhatnagar, N., Li, X., Padi, S. K., Zhang, Q., Tang, M. S. and Guo, B. 2010. Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. Cell Death Dis. 1, e105. crossref(new window)

4.
Bipat, S., van Leeuwen, M. S., Ijzermans, J. N., Comans, E. F., Planting, A. S., Bossuyt, P. M., Greve, J. W. and Stoker, J. 2007. Evidence-base guideline on management of colorectal liver metastases in the Netherlands. Neth. J. Med. 65, 5-14.

5.
Calin, G. A. and Croce, C. M. 2006. MicroRNA signatures in human cancers. Nat. Rev. Cancer 6, 857-866. crossref(new window)

6.
Cekaite, L., Rantala, J. K., Bruun, J., Guriby, M., Agesen, T. H., Danielsen, S. A., Lind, G. E., Nesbakken, A., Kallioniemi, O., Lothe, R. A. and Skotheim, R. I. 2012. MiR-9, -31, and -182 deregulation promote proliferation and tumor cell survival in colon cancer. Neoplasia 14, 868-879. crossref(new window)

7.
Cottonham, C. L., Kaneko, S. and Xu, L. 2010. miR-21 and miR-31 converge on TIAM1 to regulate migration and invasion of colon carcinoma cells. J. Biol. Chem. 285, 35293-35302. crossref(new window)

8.
Creighton, C. J., Fountain, M. D., Yu, Z., Nagaraja, A. K., Zhu, H., Khan, M., Olokpa, E., Zariff, A., Gunaratne, P. H., Matzuk, M. M. and Anderson, M. L. 2010. Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers. Cancer Res. 70, 1906-1915. crossref(new window)

9.
Dews, M., Homayouni, A., Yu, D., Murphy, D., Sevignani, C., Wentzel, E., Furth, E. E., Lee, W. M., Enders, G. H., Mendell, J. T. and Thomas-Tikhonenko, A. 2006. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat. Genet. 38, 1060-1065. crossref(new window)

10.
Fuse, M., Kojima, S., Enokida, H., Chiyomaru, T., Yoshino, H., Nohata, N., Kinoshita, T., Sakamoto, S., Naya, Y., Nakagawa, M., Ichikawa, T. and Seki, N. 2012. Tumor suppressive microRNAs (miR-222 and miR-31) regulate molecular pathways based on microRNA expression signature in prostate cancer. J. Hum. Genet. 57, 691-699. crossref(new window)

11.
Hur, K., Toiyama, Y., Okugawa, Y., Ide, S., Imaoka, H., Boland, C. R. and Goel, A. 2015. Circulating microRNA-203 predicts prognosis and metastasis in human colorectal cancer. Gut. doi: 10.1136/gutjnl-2014-308737. [Epub ahead of print] crossref(new window)

12.
Hur, K., Toiyama, Y., Schetter, A. J., Okugawa, Y., Harris, C. C., Boland, C. R. and Goel, A. 2015. Identification of a metastasis-specific MicroRNA signature in human colorectal cancer. J. Natl. Cancer Inst. 107, 1-11.

13.
Hur, K., Toiyama, Y., Takahashi, M., Balaguer, F., Nagasaka, T., Koike, J., Hemmi, H., Koi, M., Boland, C. R. and Goel, A. 2013. MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. Gut 62, 1315-1326. crossref(new window)

14.
Laurila, E. M. and Kallioniemi, A. 2013. The diverse role of miR-31 in regulating cancer associated phenotypes. Genes Chromosomes Cancer 52, 1103-1113. crossref(new window)

15.
Lewis, B. P., Burge, C. B. and Bartel, D. P. 2005. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120, 15-20. crossref(new window)

16.
Li, T., Luo, W., Liu, K., Lv, X. and Xi, T. 2015. miR-31 promotes proliferation of colon cancer cells by targeting E2F2. Biotechnol. Lett. 37, 523-532. crossref(new window)

17.
Liu, C. J., Kao, S. Y., Tu, H. F., Tsai, M. M., Chang, K. W. and Lin, S. C. 2010. Increase of microRNA miR-31 level in plasma could be a potential marker of oral cancer. Oral Dis. 16, 360-364. crossref(new window)

18.
Liu, C. J., Tsai, M. M., Hung, P. S., Kao, S. Y., Liu, T. Y., Wu, K. J., Chiou, S. H., Lin, S. C. and Chang, K. W. 2010. miR-31 ablates expression of the HIF regulatory factor FIH to activate the HIF pathway in head and neck carcinoma. Cancer Res. 70, 1635-1644. crossref(new window)

19.
Lynam-Lennon, N., Reynolds, J. V., Marignol, L., Sheils, O. M., Pidgeon, G. P. and Maher, S. G. 2012. MicroRNA-31 modulates tumour sensitivity to radiation in oesophageal adenocarcinoma. J. Mol. Med (Berl). 90, 1449-1458. crossref(new window)

20.
Schee, K., Boye, K., Abrahamsen, T. W., Fodstad, O. and Flatmark, K. 2012. Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer. BMC Cancer 12, 505. crossref(new window)

21.
Siegel, R. L., Miller, K. D. and Jemal, A. 2016. Cancer statistics, 2016. CA. Cancer J. Clin. 66, 7-30. crossref(new window)

22.
Siow, M. Y., Ng, L. P., Vincent-Chong, V. K., Jamaludin, M., Abraham, M. T., Abdul Rahman, Z. A., Kallarakkal, T. G., Yang, Y. H., Cheong, S. C. and Zain, R. B. 2014. Dysregulation of miR-31 and miR-375 expression is associated with clinical outcomes in oral carcinoma. Oral Dis. 20, 345-351. crossref(new window)

23.
Slaby, O., Svoboda, M., Fabian, P., Smerdova, T., Knoflickova, D., Bednarikova, M., Nenutil, R. and Vyzula, R. 2007. Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology 72, 397-402.

24.
Sossey-Alaoui, K., Downs-Kelly, E., Das, M., Izem, L., Tubbs, R. and Plow, E. F. 2011. WAVE3, an actin remodeling protein, is regulated by the metastasis suppressor microRNA, miR-31, during the invasion-metastasis cascade. Int. J. Cancer 129, 1331-1343. crossref(new window)

25.
Sun, F., Wang, J., Pan, Q., Yu, Y., Zhang, Y., Wan, Y., Wang, J., Li, X. and Hong, A. 2009. Characterization of function and regulation of miR-24-1 and miR-31. Biochem. Biophys. Res. Commun. 380, 660-665.

26.
Valastyan, S., Reinhardt, F., Benaich, N., Calogrias, D., Szasz, A. M., Wang, Z. C., Brock, J. E., Richardson, A. L. and Weinberg, R. A. 2009. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 137, 1032-1046. crossref(new window)

27.
Veerla, S., Panagopoulos, I., Jin, Y., Lindgren, D. and Hoglund, M. 2008. Promoter analysis of epigenetically controlled genes in bladder cancer. Genes Chromosomes Cancer 47, 368-378. crossref(new window)

28.
Wang, S., Li, Q., Wang, K., Dai, Y., Yang, J., Xue, S., Han, F., Zhang, Q., Liu, J. and Wu, W. 2013. Decreased expression of microRNA-31 associates with aggressive tumor progression and poor prognosis in patients with bladder cancer. Clin. Transl. Oncol. 15, 849-854. crossref(new window)

29.
Weizman, A. V. and Nguyen, G. C. 2010. Colon cancer screening in 2010: an up-date. Minerva. Gastroenterol. Dietol. 56, 181-188.

30.
Wszolek, M. F., Rieger-Christ, K. M., Kenney, P. A., Gould, J. J., Silva Neto, B., Lavoie, A. K., Logvinenko, T., Libertino, J. A. and Summerhayes, I. C. 2011. A MicroRNA expression profile defining the invasive bladder tumor phenotype. Urol. Oncol. 29, 794-801. crossref(new window)

31.
Xu, X. M., Qian, J. C., Deng, Z. L., Cai, Z., Tang, T., Wang, P., Zhang, K. H. and Cai, J. P. 2012. Expression of miR-21, miR-31, miR-96 and miR-135b is correlated with the clinical parameters of colorectal cancer. Oncol. Lett. 4, 339-345.

32.
Yamakuchi, M., Lotterman, C. D., Bao, C., Hruban, R. H., Karim, B., Mendell, J. T., Huso, D. and Lowenstein, C. J. 2010. P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis. Proc. Natl. Acad. Sci. USA 107, 6334-6339. crossref(new window)

33.
Zheng, W., Liu, Z., Zhang, W. and Hu, X. 2015. miR-31 functions as an oncogene in cervical cancer. Arch. Gynecol. Obstet. 292, 1083-1089. crossref(new window)